CIC has evaluated a wide range of other novel molecules, establishing proof-of-principle for a number of them, including:
Monoclonal antibodies
- TSLP (tezepelumab, N Engl J Med. 2014; 370(22): 2102-10)
- IL-13 (Am J Respir Crit Care Med Vol 183. pp 1007–1014, 2011)
- M1-prime (quilizumab, Sci. Transl. Med. 6, 243ra85 (2014))
- IgE (ligelizumab, J Allergy Clin Immunol. 2016 Oct;138(4):1051-1059)
- C5a (eculizumab, Expert Opin Biol Ther. 2012 Apr;12(4):529-37)
- OX40L (Clin Exp Allergy. 2014 Jan;44(1):29-37)
- IL-9 (BMC Pulm Med. 2011 Feb 28;11:14)
- IL-5Ra
Small molecules
- CysLT1/2 antagonist (Allergy 2016 Dec;71(12):1721-1727.)
- CXCR2 antagonist (Pulm Pharmacol Ther. 2016 Dec;41:34-39)
- GCR agonist (Am J Respir Crit Care Med. 2015 Jan 15;191(2):161-7)
- Olodaterol (J Allergy Clin Immunol. 2009 Dec;124(6):1217-21)
- Nicotinic receptor agonist (Can Respir J. 2015 Jul-Aug; 22(4): 230–234)
- Amino acid peptide AIM102
Antisense
- IL-4R
- ASM8 (CCR3/Bc) (Am J Respir Crit Care Med. 2008 May 1;177(9):952-8 & Allergy. 2011 Sep;66(9):1242-8)